MYO

Myomo Inc

Add to Watchlist

Advanced Chart

3.200

-0.160(-4.760%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.470

Open

3.370

VWAP

3.27

Vol

1.13M

Mkt Cap

115.13M

Low

3.160

Amount

3.70M

EV/EBITDA(TTM)

Total Shares

28.81M

99.36M

EV/OCF(TTM)

P/S(TTM)

3.39

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteran’s administration, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

9.17M

+21.89%

13.43M

+45.8%

18.01M

+49.24%

Estimates Revision

The market is revising Upward the revenue expectations for Myomo, Inc. (MYO) for FY2025, with the revenue forecasts being adjusted by 17.34% over the past three months. During the same period, the stock price has changed by -47.11%.

Revenue Estimates for FY2025

Revise Upward

+17.34%

In Past 3 Month

Stock Price

Go Down

-47.11%

In Past 3 Month

5 Analyst Rating

189.06% Upside

Wall Street analysts forecast MYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYO is 9.25 USD with a low forecast of 6.75 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

189.06% Upside

Current: 3.200

Low

6.75

Averages

9.25

High

11.00

189.06% Upside

Current: 3.200

Low

6.75

Averages

9.25

High

11.00

Craig-Hallum

Craig Knickerbocker

Strong Buy

Maintains

$11 → $10

2025-05-08

New

Reason

Craig-Hallum

Craig Knickerbocker

Price Target

$11 → $10

2025-05-08

New

Maintains

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$9 → $11

2025-03-17

Reason

Ascendiant Capital

Edward Woo

Price Target

$9 → $11

2025-03-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Sean Lee

Strong Buy

Maintains

$7.5 → $9.5

2025-03-12

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$7.5 → $9.5

2025-03-12

Maintains

Strong Buy

Reason

Craig-Hallum

Craig Knickerbocker

Strong Buy

Maintains

$9 → $11

2025-03-11

Reason

Craig-Hallum

Craig Knickerbocker

Price Target

$9 → $11

2025-03-11

Maintains

Strong Buy

Reason

Craig-Hallum

Craig Knickerbocker

Strong Buy

Maintains

$7 → $9

2024-12-13

Reason

Craig-Hallum

Craig Knickerbocker

Price Target

$7 → $9

2024-12-13

Maintains

Strong Buy

Reason

Myomo announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Myomo expects to use the net proceeds of the offering, together with its existing cash and cash equivalents, to accelerate its revenue growth by funding an increase in advertising expenses and headcount to support the expected revenue growth in Myomo's direct billing channel, along with investments in systems to support growth in the O&P channel and in scaling its operations. In addition, the net proceeds of the offering will be used to fund product development and sustaining engineering activities to enhance the current MyoPro product line and to develop the next generation of Myomo's products, with the remainder for working capital and general corporate purposes. Craig-Hallum Capital Group is acting as the sole managing underwriter for the offering.

HC Wainwright & Co.

Sean Lee

Strong Buy

Reiterates

$7.5

2024-11-13

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$7.5

2024-11-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Myomo Inc (MYO.A) is -28.80, compared to its 5-year average forward P/E of -11.18. For a more detailed relative valuation and DCF analysis to assess Myomo Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.18

Current PE

-28.80

Overvalued PE

2.66

Undervalued PE

-25.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.09

Current EV/EBITDA

117.81

Overvalued EV/EBITDA

13.60

Undervalued EV/EBITDA

-35.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.63

Current PS

3.32

Overvalued PS

4.22

Undervalued PS

1.03